CarboHyde

Our team is splitting forces at #jpm today. Milo and Szabi learn about innovations in regulatory aspects from KOLs like #fda comissioner Robert Califf. Tamas attends panels and pitches at an investments and licensing event featuring BD groups and venture arms of global #bigpharma How exciting!

Still have one day until #jpm starts. Enjoy it guys! Milo Malanga PhD Szabolcs Béni Tamas Sohajda

Check out our latest #cyclodextrin review fresh from the oven on cationic cyclodextrins for drug and nucleic acid delivery. This contribution to science is a fruit of our collaboration with Eötvös Loránd University and Semmelweis University (Szabolcs Béni and Adila Nazli). Special thanks to Milo Malanga PhD and Tamas Sohajda as well as Bicyclos HEurope for the funding. #genetherapy #drugdelivery https://lnkd.in/d26NfrAN

There are good and bad exponential curves. This one is a good one. The graph shows how AI-discovered molecules in clinical trials have shot up since 2014. Sure, the black bar (actual launches) is still tiny - getting through all clinical trial phases is not easy. But I'm convinced hashtag #AI will get better at predicting which molecules are most likely to succeed in trials. Exciting times ahead! We might just be at the cusp of a golden age in #drugdevelopment. https://lnkd.in/ew7VFASU

Fantastic #antiinflammatory #cyclodextrin application by Goethe-Universität Frankfurt a. Main Inflammation plays a critical role in the pathophysiology of many diseases, and dysregulation of the involved signaling cascades often culminates in uncontrollable disease progression and, ultimately, chronic manifestation. Cyclodextrins (CDs), particularly β-CD, have gained attention as biocompatible biomaterials with intrinsic anti-inflammatory properties, and chemical modification of their backbone offers a promising strategy to enhance their physicochemical properties, adaptability, and therapeutic potential. In a human macrophage model, CD nanoparticles demonstrated superior anti-inflammatory activity, with derivative-specific effects tied to their physicochemical properties, surpassing the soluble β-CD control. The findings of this study underscore the potential of cyclodextrin-based nanoparticles as versatile biomaterials for treating the complex pathophysiology of various acute and chronic inflammation-associated disorders. https://lnkd.in/dKMvzyhn

We are big fans of leaving the comfort zone to explore and learn. And you? We are learners. We particularly enjoy discussing wild ideas with new people, brainstorming about impossible projects, and exploring untouched areas. We can only grow when we get out of our comfort zone.

Direct Continuous Flow Synthesis of Two Difficult Polypeptides Using β-Cyclodextrins Wonderful paper from Hungary by Szaniszló Szebasztián, Gitta Schlosser, Viktor Farkas and Perczel András Results show that the use of β-CyD as an additive results in a significant (8–19%) increase in the purity of the crude polypeptide compared to that determined by our reference method. https://lnkd.in/dxCxuRTV

What's inside the Top 15 Drugs by Revenue in 2024? Keytruda (Merck) Dosage Form: Solution for infusion (25 mg/mL). Active Ingredient: Pembrolizumab. Excipients: L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80, water for injections. Ozempic (Novo Nordisk) Dosage Form: Solution for subcutaneous injection (prefilled pen). Active Ingredient: Semaglutide. Excipients: Disodium phosphate dihydrate, propylene glycol, phenol, water for injections. Dupixent (Sanofi/Regeneron) Dosage Form: Solution for subcutaneous injection (prefilled syringe or pen). Active Ingredient: Dupilumab. Excipients: L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate trihydrate, sucrose, water for injections. Biktarvy (Gilead) Dosage Form: Film-coated tablets. Active Ingredients: Bictegravir, emtricitabine, tenofovir alafenamide. Excipients: Croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide red. Read the whole article at https://lnkd.in/dAZVeBQj

CarboHyde formulation team is growing! Onboarding of Tamas Kiss, PhD, welcome to our group, we look forward to our common journey with great excitement!

Cyclodextrins in Liposomes? Why not combine the two technologies? Cyclodextrin complexes have been widely used in pharmaceutical applications, but disadvantages such as the rapid clearance of cyclodextrins from the blood stream after in vivo administration or their replacement by other molecules in the biological medium with higher luminal affinity for cyclodextrins limit the application of cyclodextrins as drug carriers. Liposome-encapsulated hydrophobic drugs have low and unstable drug loading rates. Drug-in-CD-in-liposome (DCL), which encapsulate cyclodextrin inclusion complexes into liposomes, combine the advantages of both delivery systems, can effectively avoid the leakage and rapid release of lipophilic drugs in the lipid bilayer, and help to maintain the integrity of liposomes. Such cyclodextrin-liposome nanocomposites also have the possibility to deliver actives from ocular surface to the posterior segment of the eye: https://lnkd.in/dju-dKGF Here is a great review about the topic also: https://lnkd.in/dsHTX978